通化东宝：甘精胰岛素注射液获得境外上市许可

Core Viewpoint - Tonghua Dongbao (600867) has received approval from the Ministry of Health of the Republic of the Union of Myanmar for the marketing license of its product, Insulin Glargine Injection [1] Group 1: Product Information - Insulin Glargine is a long-acting insulin analog that requires daily injection [1] - The product has a 24-hour duration of action after injection, providing a stable reduction in blood glucose levels without peak concentration [1]